Skip to main content
. 2022 May 27;10(8):561–570. doi: 10.1016/S2213-8587(22)00131-0

Table.

Non-COVID-19-related deaths in people with diabetes and baseline characteristics of participants in the 2021 cohort and the 2019 comparator cohort.

2021
2019
Number of people alive as of July 3 Non-COVID-19-related deaths Death rate per 100 000 people (95% CI) Number of people alive as of June 29 Non-COVID-19-related deaths Death rate per 100 000 people (95% CI)
Total 3 218 570 30 118 936 (925–946) 2 973 645 27 132 912 (902–923)
Annual eight care process groups*
Not received in either first or second year 1 376 270 (42·8%) 16 599 (55·1%) 1206 (1188–1225) 1 018 855 (34·3%) 13 160 (48·5%) 1292 (1270–1314)
Received in first year but not second 988 645 (30·7%) 8894 (29·5%) 900 (881–919) 584 480 (19·7%) 5166 (19·0%) 884 (860–908)
Received in second year but not first 295 060 (9·2%) 1664 (5·5%) 564 (537–592) 517 050 (17·4%) 3596 (13·3%) 695 (673–719)
Received in both years 558 595 (17·4%) 2961 (9·8%) 530 (511–550) 853 260 (28·7%) 5210 (19·2%) 611 (594–627)
Diabetes type
Type 1 diabetes 243 510 (7·6%) 963 (3·2%) 395 (371–421) 235 455 (7·9%) 918 (3·4%) 390 (365–416)
Type 2 diabetes 2 926 390 (90·9%) 28 723 (95·4%) 982 (970–993) 2 714 685 (91·3%) 26 063 (96·1%) 960 (948–972)
Other 48 670 (1·5%) 432 (1·4%) 888 (806–975) 23 500 (0·8%) 151 (0·6%) 643 (544–754)
Age, years
<40 215 515 (6·7%) 121 (0·4%) 56 (47–67) 196 925 (6·6·%) Suppressed Suppressed
40–44 122 365 (3·8%) 126 (0·4%) 103 (86–123) 112 605 (3·8%) 100 (0·4%) 89 (72–108)
45–49 197 655 (6·1%) 309 (1·0%) 156 (139–175) 188 200 (6·3%) 251 (0·9%) 133 (117–151)
50–54 288 965 (9·0%) 578 (1·9%) 200 (184–217) 267 345 (9·0%) 507 (1·9%) 190 (173–207)
55–59 365 815 (11·4%) 1013 (3·4%) 277 (260–295) 331 225 (11·1%) 843 (3·1%) 255 (238–272)
60–64 397 910 (12·4%) 1556 (5·2%) 391 (372–411) 361 050 (12·1%) 1334 (4·9%) 369 (350–390)
65–69 404 860 (12·6% 2448 (8·1%) 605 (581–629) 384 240 (12·9%) 2359 (8·7%) 614 (589–639)
70–74 429 210 (13·3%) 3947 (13·1%) 920 (891–949) 395 710 (13·3%) 3483 (12·8%) 880 (851–910)
≥75 796 280 (24·7%) 20 020 (66·5%) 2514 (2479–2549) 736 345 (24·8%) 18 136 (66·8%) 2463 (2427–2499)
Unknown 5 (<0·1%) 0 N/A 5 (<0·1%) Suppressed Suppressed
Sex
Male 1 796 265 (55·8%) 16 508 (54·8%) 919 (905–933) 1 664 320 (56·0%) 15 013 (55·3%) 902 (888–917)
Female 1 422 285 (44·2%) 13 610 (45·2%) 957 (941–973) 1 309 305 (44·0%) 12 119 (44·7%) 926 (909–942)
Unknown 25 (<0·1%) 0 N/A 20 (<0·1%) 0 N/A
Ethnicity
Asian 435 305 (13·5%) 1722 (5·7%) 396 (377–415) 378 220 (12·7%) 1488 (5·5%) 393 (374–414)
Black 153 325 (4·8%) 804 (2·7%) 524 (489–562) 134 720 (4·5%) 666 (2·5%) 494 (458–533)
Mixed 35 820 (1·1%) 170 (0·6%) 475 (406–552) 30 870 (1·0%) 153 (0·6%) 496 (420–581)
Other 60 295 (1·9%) 295 (1·0%) 489 (435–548) 54 120 (1·8%) 294 (1·1%) 543 (483–609)
Unknown 287 125 (8·9%) 2532 (8·4%) 882 (848–917) 353 315 (11·9%) 3062 (11·3%) 867 (836–898)
White 2 246 705 (69·8%) 24 595 (81·7%) 1095 (1081–1108) 2 022 405 (68·0%) 21 469 (79·1%) 1062 (1047–1076)
Deprivation, IMD quintile
1 762 465 (23·7%) 6988 (23·2%) 917 (895–938) 706 720 (23·8%) 6190 (22·8%) 876 (854–898)
2 711 915 (22·1%) 6450 (21·4%) 906 (884–928) 653 005 (22·0%) 5888 (21·7%) 902 (879–925)
3 662 655 (20·6%) 6279 (20·8%) 948 (924–971) 608 625 (20·5%) 5699 (21·0%) 936 (912–961)
4 590 085 (18·3%) 5805 (19·3%) 984 (959–1009) 547 625 (18·4%) 5158 (19·0%) 942 (916–968)
5 490 630 (15·2%) 4584 (15·2%) 934 (907–962) 456 800 (15·4%) 4188 (15·4%) 917 (889–945)
Unknown 825 (<0·1%) 12 (<0·1%) N/A 870 (<0·1%) 9 (<0·1%) N/A

Data are n (%) unless otherwise stated. IMD quintile 1 represents most deprived and IMD quintile 5 represents least deprived. All mortality data referring to between one and five people are suppressed in order to protect patient confidentiality. IMD=indices of multiple deprivation. NA=not assessed.

*

For 2021 data, first year refers to April 1, 2019, to March 31, 2020, and second year refers to April 1, 2020 to March 31, 2021; for 2019 data, first year refers to April 1, 2017, to March 31, 2018, and second year refers to April 1, 2018, to March 31, 2019.